FDA PDUFA goal date of August 15, 2025, for TNX-102 SL for the management of fibromyalgia; if approved, TNX-102 SL would ...

Tonix Pharmaceuticals has no tonic for cocaine intoxication, with the biopharma terminating a midstage trial for the ...

About Tonix Pharmaceuticals Holding Corp. Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small ...

Combination treatment of TFF2 with anti-PD1 antibody was associated with the activation of cancer-killing CD8+ T Cells and ...

Tonix Pharmaceuticals Holding Corp. announced that it will present an oral presentation and lead a panel discussion at the World Vaccine Congress Washington 2025 from April 22-24 in Washington ...

Tonix Pharmaceuticals presented promising data on TNX-1700 for gastric and colorectal cancers, enhancing anti-PD1 therapy effectiveness in preclinical models. Tonix Pharmaceuticals has announced ...

As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to ...

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) announced the outcomes of its annual shareholder meeting held on Thursday, May 8, 2025. The meeting saw the approval of seven key proposals, with 46.7 ...

As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to ...

FDA PDUFA goal date of August 15, 2025, for TNX-102 SL for the management of fibromyalgia; if approved, TNX-102 SL would become the first new drug for treating fibromyalgia in more than 15 years Annou ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...